Introduction
============

MicroRNAs (miRNAs) are single-stranded RNAs of 20--30 nt that mediate post-transcriptional gene silencing. Over the past decade, it has been reported that miRNAs play key roles in the initiation and progression of human cancer. For instance, the let-7 family of miRNAs can target oncogenes, such as *MYC* and *RAS* family members, to inhibit tumor growth ([@ref-17]; [@ref-18]). [@ref-31] reported that the miR-17--92 cluster interacts with *E2F1* and *MYC* to promote tumor development in lung cancer. Although individual miRNAs can have either tumorigenic or tumor-suppressive functions, [@ref-26] analyzed 217 mammalian miRNAs from 334 samples and found that miRNAs were globally down-regulated in cancers. [@ref-39] indicated that this widespread down-regulation of miRNAs is due to a failure in a Drosha processing step, suggesting that miRNA biogenesis may be impaired in cancer.

The majority of the miRNA biogenesis pathway is shown in [Fig. 1](#fig-1){ref-type="fig"}. In the nucleus, microRNA genes are transcribed as primary miRNAs (pri-miRNAs) by RNA polymerase II (Pol II). These long pri-miRNAs are then cleaved by the double-stranded RNaseIII enzyme Drosha and its essential cofactor DGCR8 ([@ref-8]; [@ref-22]), generating pre-miRNAs (∼65 nt). Pre-miRNAs are then exported from the nucleus to the cytoplasm by Exportin-5 (*XOP5*) and its cofactor Ran ([@ref-43]). Following nuclear export, the pre-miRNA loop is cleaved by the RNaseIII enzyme Dicer to generate miRNA duplexes ([@ref-32]). Dicer, TRBP or PACT, and Argonaute proteins Ago1--4 regulate the processing of pre-miRNA and the assembly of the RNA-induced silencing complex (RISC) ([@ref-5]). Together with members of the GW182 family of proteins, one strand of the RNA duplex remains anchored to the Ago protein as the mature miRNA while the other one degraded ([@ref-11]).

![MiRNA biogenesis pathway.](peerj-04-2706-g001){#fig-1}

As mentioned in [Fig. 1](#fig-1){ref-type="fig"}, the Drosha, DGCR8, Exportin-5, Ran, and Dicer proteins are crucial components in the miRNA biogenesis pathway. Dysregulation of these miRNA-processing machinery components may disturb the product, leading to disease thus this study was focused on this five core components in miRNA biogenesis pathway and explore its link with cancer risk. Indeed, the expression levels of Drosha and Dicer are down-regulated in ovarian cancer ([@ref-20]) and neuroblastomas ([@ref-23]), while DGCR8 is up-regulated in esophageal cancer ([@ref-37]), bladder cancer ([@ref-3]), and prostate cancer. Exportin-5 is also down-regulated in bladder cancer ([@ref-3]). There are several studies implicating single-nucleotide polymorphisms (SNPs) present in those five miRNA biogenesis pathway genes were link with cancer risk, e.g., [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719) T\>C in *DROSHA*; [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309) G\>A and [rs1640299](http://www.ncbi.nlm.nih.gov/snp/?term=rs1640299) T\>G in *DGCR8*; [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077) in *XPO5*; [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035) C\>T and [rs3803012](http://www.ncbi.nlm.nih.gov/snp/?term=rs3803012) A\>G in *RAN*; and [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035) T\>C, [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330) A\>G, and [rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078) T\>A in *DICER1*. However, the conclusions of previous studies remain inconsistent. A comprehensive review and meta-analysis of SNPs in miRNA biogenesis pathway components is needed. In this study, a meta-analysis was conducted to evaluate the association between SNPs in five genes (*DROSHA*, *DGCR8*, *XPO5*, *RAN,* and*DICER1*) involved in the canonical microRNA biogenesis pathway and human cancer risk.

Materials and Methods
=====================

Identification of eligible studies
----------------------------------

Two reviewers (He and Zhu) searched the electronic databases PubMed, Google Scholar, CBM, and CNKI for studies containing at least one of the five gene names and its aliases ("*DROSHA ETOHI2 HSA242976 RANSE3L RN3 RNASE3L RNASEN*," "*DGCR8 C22orf12 DGCRK6 Gy1 pahsa*," "*XPO5 exp5*," "*RAN ARA24 Gsp1 TC4*," or "*DICER DCR1 Dicer1e HERNA K12H4 8-LIKE MNG1 RMSE2"*). The following terms were also used in each search: cancer, carcinoma, neoplasm, tumor, gene name and its aliases, gene polymorphism, allele, and variation. The search was limited to articles published in English or Chinese through Jun 21, 2016.The reference lists of pertinent articles were checked as well. Articles were included in the study if (1) they reported a correlation between a SNP from *DROSHA*([rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719)), *DGCR8*([rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309) or [rs1640299](http://www.ncbi.nlm.nih.gov/snp/?term=rs1640299)), *XPO5*([rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077)), *RAN*([rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035)), or *DICER1*([rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035), [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330), or [rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078)) and cancer risk; (2) they presented a case-control study; and (3) genotype frequencies were available. Articles were excluded if (1) they were review articles or focused on animals; (2) they lacked data necessary for a systematic review; or (3) the control subjects exhibited a departure from Hardy--Weinberg equilibrium (HWE). In the case where there was more than one publication using the same samples, the article with the most recent publication date was selected. The two reviewer reached consensus on each study.

Data extraction
---------------

The following information were extracted by two reviewers (He and Zhao) independently and disagreement were solved by discussion: first author's name, publication year, country of origin, ethnicity, cancer types, genotype frequencies in case and control groups, HWE results, and source of control samples. Quality assessment of articles was conducted using the Newcastle-Ottawa Quality Assessment Scale (NOS) ([@ref-36]). If more than one type of cancer or multistage research was involved in a single article, data were extracted as independent articles.

Statistical analysis
--------------------

Hardy--Weinberg equilibrium (HWE) was evaluated in the controls of each SNP using the Chi-square test. Odds ratios (OR) with 95% confidence intervals (CI) were calculated by the *Z* test to evaluate the association between the SNPs and cancer susceptibility under a dominant model, *P* \< 0.05 was considered statistically significant. The heterogeneity between articles was examined using a *Q*-test and *I*^2^ index ([@ref-14]). Random-effects models ([@ref-9]) were used if heterogeneity between articles was reported (*P* \< 0.10, *I*^2^ \> 50%), otherwise fixed-effects models ([@ref-28]) were applied. Sensitivity analyses were performed with a leave-one-out method by removing each article one at a time and repeating the analysis. Publication bias was evaluated by Egger's test and Begg's test, with a *P*-value \> 0.10 considered evidence for no potential publication bias ([@ref-1]; [@ref-10]). All *P* value were two sided and all analyses were performed by Stata statistical software (Version 12.0; StataCorp, College Station, Texas USA).

Results
=======

Study characteristics
---------------------

A total of 832 relevant articles were identified based on our search strategy. Article selection procedures for all SNPs from *DROSHA*, *DGCR8*, *XPO5*, *RAN*, and *DICER1* are shown in a flow chart ([Fig. 2](#fig-2){ref-type="fig"}). As a result, 22 case-control articles including nine SNPs ([rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719), [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309), [rs1640299](http://www.ncbi.nlm.nih.gov/snp/?term=rs1640299), [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077), [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035), [rs3803012](http://www.ncbi.nlm.nih.gov/snp/?term=rs3803012), [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035), [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330), and [rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078)) met the inclusion criteria for this study. Characteristics of the eligible studies are summarized in [Table 1](#table-1){ref-type="table"}. Among the applicable articles, 15 articles were about studies of subjects who were of Asian descent, and seven articles were about studies of subjects who were of Caucasian descent. The analyzed articles for each SNP are shown in [Table S1](#supp-3){ref-type="supplementary-material"}.

![Flow diagram of the study selection process.](peerj-04-2706-g002){#fig-2}
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###### Characteristics of the studies eligible for meta-analysis.

![](peerj-04-2706-g005)

  Author      Year   Cancer type                Country    Ethnicity   Controls   Case   Control   Method     Polymorphism site                                                                                                                                                                                                                                                                                                                                                          nos
  ----------- ------ -------------------------- ---------- ----------- ---------- ------ --------- ---------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----
  [@ref-15]   2008   renal cell carcinoma       American   Caucasian   PB         279    278       SNPlex     [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309), [rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078), [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330), [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719), [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035)                                                                     8
  [@ref-41]   2008   bladder cancer             American   Caucasian   HB         746    746       SNPlex     [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309), [rs1640299](http://www.ncbi.nlm.nih.gov/snp/?term=rs1640299), [rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078), [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330), [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077)                                                                 7
  [@ref-42]   2008   esophageal cancer          American   Caucasian   HB         346    346       SNPlex     [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309), [rs1640299](http://www.ncbi.nlm.nih.gov/snp/?term=rs1640299), [rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078), [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330), [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035), [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077)       7
  [@ref-19]   2010   lung cancer                Korea      Asian       HB         100    100                  [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309), [rs1640299](http://www.ncbi.nlm.nih.gov/snp/?term=rs1640299), [rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078), [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330), [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719), [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035)       7
  [@ref-38]   2011   breast cancer              Korea      Asian       HB         559    567       TaqMan     [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035), [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077)                                                                                                                                                                                                                                                     7
  [@ref-27]   2012   head and neck cancer       China      Asian       HB         397    900       TaqMan     [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035), [rs3803012](http://www.ncbi.nlm.nih.gov/snp/?term=rs3803012)                                                                                                                                                                                                                                                 7
  [@ref-4]    2013   cervical carcinoma         China      Asian       HB         1486   1549      TaqMan     [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035), [rs3803012](http://www.ncbi.nlm.nih.gov/snp/?term=rs3803012)                                                                                                                                                                                                                                                 7
  [@ref-16]   2013   breast cancer              China      Asian       HB         878    900       TaqMan     [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309), [rs1640299](http://www.ncbi.nlm.nih.gov/snp/?term=rs1640299), [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035), [rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078), [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719), [rs3803012](http://www.ncbi.nlm.nih.gov/snp/?term=rs3803012)   7
  [@ref-25]   2013   hepatocellular carcinoma   China      Asian       HB         1300   2688      TaqMan     [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309), [rs164029](http://www.ncbi.nlm.nih.gov/snp/?term=rs164029), [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035), [rs3803012](http://www.ncbi.nlm.nih.gov/snp/?term=rs3803012)                                                                                                                         7
  [@ref-35]   2013   colorectal cancer          Czech      Caucasian   HB         197    202       TLDA       [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035)                                                                                                                                                                                                                                                                                                               7
  [@ref-45]   2013   bladder cancer             China      Asian       HB         685    730       TaqMan     [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035), [rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078), [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330), [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719)                                                                                                                             7
  [@ref-33]   2014   oral cancer                India      Asian       HB         451    452       Taqman     [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035)                                                                                                                                                                                                                                                                                                                   7
  [@ref-6]    2015   Colorectal Cancer          Korean     Asian       HB         408    400       PCR-RFLP   [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330), [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719), [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035), [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077)                                                                                                                                 7
  [@ref-29]   2015   Lymphocytic Leukemia       Spanish    Caucasian   HB         123    391       Taqman     [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309), [rs1640299](http://www.ncbi.nlm.nih.gov/snp/?term=rs1640299), [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035),[rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078), [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719), [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035)        7
  [@ref-40]   2015   gastric cancer             China      Asian       HB         137    142                  [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330), [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035), [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077)                                                                                                                                                                                           7
  [@ref-47]   2015   colorectal cancer          China      Asian       HB         163    142                  [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330), [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035), [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077)                                                                                                                                                                                           7
  [@ref-49]   2013   lung cancer                China      Asian       HB         600    600       TaqMan     [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035)                                                                                                                                                                                                                                                                                                               7
  [@ref-48]   2013   esophageal cancer          China      Asian       HB         380    380                  [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330)                                                                                                                                                                                                                                                                                                               7
  [@ref-46]   2012   gastric cancer             China      Asian       HB         1674   1852      TaqMan     [rs3803012](http://www.ncbi.nlm.nih.gov/snp/?term=rs3803012), [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035)                                                                                                                                                                                                                                                 7
  [@ref-2]    2015   esophageal cancer          Europe     Caucasian   HB         600    600       TaqMan     [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035), [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077)                                                                                                                                                                                                                                                         7
  [@ref-13]   2014   Lymphocytic Leukemia       Spanish    Caucasian   HB         213    387                  [rs1640299](http://www.ncbi.nlm.nih.gov/snp/?term=rs1640299)                                                                                                                                                                                                                                                                                                               7

Quantitative synthesis
----------------------

Evaluations of the associations between miRNA biogenesis pathway component SNPs and human cancer risk are shown in [Table 2](#table-2){ref-type="table"} and [Fig. 3](#fig-3){ref-type="fig"}.

10.7717/peerj.2706/table-2

###### Analysis of associations between SNPs from *DROSHA*, *DGCR8*, *XPO5*, *RAN*, and *DICER1* and cancer risk.

![](peerj-04-2706-g006)

  Gene(locus)                                                                                        Position    studies   Method   Cases /controls   WW vs.WM+MM[^a^](#table-2fn1){ref-type="fn"}   *P*[^b^](#table-2fn2){ref-type="fn"}   *I*^2^     WW vs. WM+MM[^a^](#table-2fn1){ref-type="fn"}   *P*[^c^](#table-2fn3){ref-type="fn"}   *I*^2^   WW vs.WM+MM[^a^](#table-2fn1){ref-type="fn"}   *P*[^d^](#table-2fn4){ref-type="fn"}   *I*^2^
  -------------------------------------------------------------------------------------------------- ----------- --------- -------- ----------------- ---------------------------------------------- -------------------------------------- ---------- ----------------------------------------------- -------------------------------------- -------- ---------------------------------------------- -------------------------------------- ----------
  *DROSHA*(5p13.3)                                                                                                                                                                                                                                                                                                                                                                                                                           
  [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719) T\>C                                      3^^′^^UTR   5         R        1982/2293         0.91(0.75,1.10)                                0.209                                  36.2       1.34(0.78,2.30)                                 0.070                                  69.6     1.05(0.83,1.33)                                0.026                                  63.9
  *DGCR8*(22q11.2)                                                                                                                                                                                                                                                                                                                                                                                                                           
  [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309) G\>A[^e^](#table-2fn5){ref-type="fn"}   3^^′^^UTR   7         F        3327/3658         **1.44(1.13,1.83)**                            **0.561**                              **0.0**    1.04(0.78,1.39)                                 0.147                                  47.8     **1.22(1.04,1.42)**                            **0.190**                              **31.2**
  [rs1640299](http://www.ncbi.nlm.nih.gov/snp/?term=rs1640299) T\>G                                  3^^′^^UTR   7         R        2610/3046         1.07(0.90,1.28)                                0.571                                  0.0        1.22(0.85,1.75)                                 0.017                                  70.7     1.20(0.94,1.54)                                0.038                                  46.1
  *XPO5*(6p21.1)                                                                                                                                                                                                                                                                                                                                                                                                                             
  [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077) A\>G                                      3^^′^^UTR   7         F        8065/5478         0.83(0.66,1.03)                                0.652                                  0.0        0.95(0.88,1.03)                                 0.260                                  25.7     0.94(0.87,1.01)                                0.463                                  0.0
  *RAN*(12q24.3)                                                                                                                                                                                                                                                                                                                                                                                                                             
  [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035) C\>T                                      3^^′^^UTR   9         R        7702/5335         1.40(0.72,2.69)                                0.001                                  92.6       0.99(0.73,1.33)                                 0.002                                  79.2     1.17(0.87,1.57)                                0.000                                  88.7
  [rs3803012](http://www.ncbi.nlm.nih.gov/snp/?term=rs3803012) A\>G                                  3^^′^^UTR   5         F        5642/6489         0.98(0.87,1.11)                                0.494                                  0.0        --                                              --                                     --       --                                             --                                     --
  *DICER1*(14q32.13)                                                                                                                                                                                                                                                                                                                                                                                                                         
  [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035) T\>C                                  3^′^UTR     10        F        7783/8925         **1.13(1.04,1.22)**                            **0.163**                              **33.2**   1.21(0.90,1.62)                                 0.182                                  44.0     **1.13(1.05,1.22)**                            **0.188**                              **27.8**
  [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330) A\>G                                  3^′^UTR     9         R        3222/3240         1.02(0.89,1.18)                                0.000                                  79.6       0.90(0.73,1.10)                                 0.396                                  0.0      0.98(0.87,1.10)                                0.001                                  70.9
  [rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078) T\>A                                      3^′^UTR     7         F        3102/3419         1.01(0.81,1.26)                                0.889                                  0.0        1.13(0.97,1.32)                                 0.116                                  49.3     1.09(0.96,1.24)                                0.339                                  11.8

**Notes.**

W: major allele M: minor allele.

Asian population.

Caucasian population.

All over.

WM+MM vs. WW.

Method: F, Fixed model; R, Random model.

A significant association was observed between cancer risk and the *DGCR8* [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309) G\>A polymorphism in the overall pooled analysis (GA + AA vs. GG: OR 1.22, 95% CI \[1.04--1.42\]) and in the Asian samples (GA + AA vs. GG: OR 1.44, 95% CI \[1.13--1.83\]). For the [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035) T\>C variant in *DICER1*, a significant (13%) increase in cancer risk was found in the overall pooled analysis (AA vs. AC + CC: OR 1.13, 95% CI \[1.05--1.22\]). Subgroup analysis determined by sample ethnicity revealed that genotypes containing the major allele increased the risk of cancer in those of Asian descent (AA vs. AC + CC: OR 1.13, 95% CI \[1.04--1.22\]).

![Forest plot for the relationship between the microRNA biogenesis pathway genes polymorphism and cancer risk.](peerj-04-2706-g003){#fig-3}

Sensitivity analysis
--------------------

Sensitivity analysis was conducted to assess the robustness of the results. Each individual article was omitted to measure its effect on the pooled ORs ([Fig. S3](#supp-2){ref-type="supplementary-material"}). The sensitivity analysis forest plot showed that no individual article dramatically affected the pooled OR for any SNP.

![Funnel plot for publication bias test. OR, odds ratio; SE, standard error.](peerj-04-2706-g004){#fig-4}

Publication bias
----------------

Funnel plots did not show obvious asymmetry for any locus ([Fig. 4](#fig-4){ref-type="fig"}). The results of Egger's test and Begg's test revealed that [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719) in *DROSHA* presented publication bias (Begg's test: *Z* = 1.47, *P* = 0.14; Egger's test: *P* = 0.09, 95% CI \[−0.87--7.07\]), suggesting that the results for [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719) should be treated with caution. For the other SNPs, neither test indicated potential publication bias ([Table 3](#table-3){ref-type="table"}).

Discussion
==========

In this study, we searched for articles indicating an association between SNPs in miRNA biogenesis pathway genes and human cancer risk. A total of 21 articles were identified, and 9 SNPs were evaluated for association with cancer susceptibility. The results demonstrated that the GG genotype of [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309) in *DGCR8* was significantly rarer among cases compared with controls in the overall pooled analysis and the TT genotype of [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035) in *DICER1* was associated with a 13% increase in cancer risk. In addition significant associations were found in the Asian population but not in the Caucasian population, which suggested a possible ethnic difference in the genetic background and the environment. Significant association were not observed in *DROSHA* ([rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719) T\>C), *XPO5* ([rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077) A\>G) and *RAN* ([rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035) C\>T, rs3803012A\>G). Genome-wide association studies (GWAS) involving associations between esophageal adenocarcinoma risk and *RAN*([rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035) C\>T) or *XOP5*([rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077) A\>G) were included in this meta-analysis ([@ref-2]). The results of our meta-analysis were consistent with the findings of these GWAS publications (OR 1.10, 95% CI \[0.76--1.59\] compared with OR 1.17, 95% CI \[0.87--1.57\] in our meta-analysis for *RAN* [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035) C\>T and OR 0.94, 95% CI \[0.85--1.04\] compared with OR 0.93, 95% CI \[0.87--1.01\] in our meta-analysis for *XOP5* [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077) A\>G).
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###### Results of Egger's and Begg's tests for publication bias.
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  Category                                                            Studies   Begg's test   Egger's test                  
  ------------------------------------------------------------------- --------- ------------- -------------- -------------- ------
  *DROSHA*                                                                                                                  
  [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719) T\>C       5         1.47          0.14           (−0.87,7.07)   0.09
  *DGCR8*                                                                                                                   
  [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309) G\>A     7         1.20          0.23           (−4.79,0.79)   0.13
  [rs1640299](http://www.ncbi.nlm.nih.gov/snp/?term=rs1640299) T\>G   7         1.20          0.23           (−2.39,5.13)   0.39
  *XPO5*                                                                                                                    
  [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077) A\>G       7         0.3           0.76           (−0.20,0.12)   0.53
  *RAN*                                                                                                                     
  [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035) C\>T       9         1.15          0.25           (−2.66,5.07)   0.49
  [rs3803012](http://www.ncbi.nlm.nih.gov/snp/?term=rs3803012) A\>G   5         −1.32         0.19           (−3.75,1.80)   0.39
  *DICER1*                                                                                                                  
  [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035) T\>C   10        0.72          0.47           (−2.11,4.20)   0.76
  [rs3742330](http://www.ncbi.nlm.nih.gov/snp/?term=rs3742330) A\>G   9         0.10          0.92           (−2.98,8.01)   0.32
  [rs13078](http://www.ncbi.nlm.nih.gov/snp/?term=rs13078) T\>A       7         −1.05         0.293          (−3.81,2,91)   0.77

DROSHA and its essential cofactor DGCR8 are critical protein that executes the initial step in microRNA processing ([@ref-22]). Dysregulation of DROSHA and DGCR8 has been observed in many cancers such as epithelial skin cancer ([@ref-34]), breast cancer ([@ref-4]) and ovarian cancer ([@ref-12]). Pre-miRNAs are exported into the cytoplasm to generate mature miRNAs through XOP5 and it cofactor RAN ([@ref-24]), some heterozygous *XPO5* variations were found in colon, gastric and endometrial cancer ([@ref-30]). The variation of *XPO5* impairs pre-miRNA exportation and lead to defect in miRNAs biogenesis. Genetic and epigenetic association studies reported that the genetic variation of *XPO5* was associated with the risk of breast cancer ([@ref-21]). DICER1 is another enzymes that plays critical role in the cleavage of pre-miRNAs into their mature form ([@ref-24]). The variation of DICER1 were correlated with cancer risk through affecting cell proliferation and apoptosis ([@ref-7]) all those component are key enzymes in miRNAs mature process. Since the global impairment of mature miRNAs is emerging as a common feature of human tumors ([@ref-30]), and given the critical functions of Drosha, DGCR8, Exportin-5, Ran, and Dicer in miRNA biogenesis, it is logical to presume that genetic polymorphisms in these genes may affect the processing of miRNAs and, thus, cancer risk. As a matter of fact, several studies have shown significantly association about single nucleotide polymorphism of MicroRNA biogenesis pathway gene with different cancer risk. [@ref-6] reported that *RAN* [rs14035](http://www.ncbi.nlm.nih.gov/snp/?term=rs14035) CT heterozygotes and *XPO5* [rs11077](http://www.ncbi.nlm.nih.gov/snp/?term=rs11077) AA carriers experienced reduced risk of colorectal cancer in Korean population. [@ref-21] performed both genetic and epigenetic association studies of XPO5 in a case-control study of breast cancer and found *XPO5* [rs11544382](http://www.ncbi.nlm.nih.gov/snp/?term=rs11544382) was associated with cancer risk (the analysis of *XPO5* [rs11544382](http://www.ncbi.nlm.nih.gov/snp/?term=rs11544382) with cancer risk was not performed due to lack of availed data). [@ref-4] analyzed 1,486 cervical cases and 1,549 cancer-free controls in Chinese population and found that a single nucleotide polymorphisms in *DICER* [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035) and RAN [rs3803012](http://www.ncbi.nlm.nih.gov/snp/?term=rs3803012) was associated with cervical cancer risk. A case-control and further research conducted by [@ref-16] suggested that DGCR8 [rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309) G\>A might affect breast cancer risk through interrupting the miRNA binding. However, conclusions of miRNA biogenesis pathway genes polymorphisms and cancer risk remain inconsistent, which may cause by the heterogeneity of the cancer subtype, sample size and the ethnicity of patients. [@ref-44] conducted a meta-analysis synthesizes sevens studies with multi-type cancer and found the C allele of the DICER [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035) polymorphism probably decreases cancer risk (We included more studies in our studies and found the same results in DICER [rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035)). This study based on the association of a single SNP or gene with cancer risk, which may weaken gene's biological value. All five miRNA biogenesis pathway were evaluated in our analysis, which may provide a more comprehensive view of the true system. To the best of our knowledge, this study represents the first meta-analysis to focus on the association between human cancer risk and SNPs across the entire miRNAs biogenesis pathway.

Sensitivity analysis indicated that the results of our study were robust. Egger's test and Begg's test revealed that publication bias has little influence on the results, with the exception of [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719) in *DROSHA*, suggesting that the results for [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719) should be considered with caution. Despite these results, some limitations still apply to this meta-analysis. First, all results were based on unadjusted estimates because few adjusted ORs were reported in the included articles. Biases caused by confounding variables such as sex, age, and smoking may therefore persist. Secondly, heterogeneity among different cancers may cause real effects to be hidden when pooling all cancer types. A stratified analysis based on cancer type was not performed due to the lack of an adequate number of publications for a single cancer type. Third, although the results of the publication bias analysis indicated no bias for any locus except [rs10719](http://www.ncbi.nlm.nih.gov/snp/?term=rs10719), it is possible that there actually was publication bias but that it was not identified by the Egger's and Begg's tests due to the low power given to the small number of studies ([@ref-1]; [@ref-10]). Finally, we applied a traditional fixed model and a random model to pooled multiple-ethnicity samples; neither of these approaches is ideal for capturing the heterogeneity of effects observed across different ethnic populations ([@ref-50]).

In summary, this meta-analysis suggests a potential role of the miRNA biogenesis genes *DGCR8* ([rs417309](http://www.ncbi.nlm.nih.gov/snp/?term=rs417309) G\>A) and *DICER1* ([rs1057035](http://www.ncbi.nlm.nih.gov/snp/?term=rs1057035) T\>C) in cancer risk. The identified markers can thus potentially be used as biomarkers for cancer diagnosis. However, future well-designed studies, including those focused on a single cancer type with larger sample sizes, are still needed to confirm these observed associations due to the limitations mentioned above.
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